COVID-19
Biosimilars
Cataract Therapeutics
DME
Gene Therapy
Workplace
Ptosis
Optic Relief
Imaging
Geographic Atrophy
AMD
Presbyopia
Ocular Surface Disease
Practice Management
Pediatrics
Surgery
Therapeutics
Optometry
Retina
Cataract
Pharmacy
IOL
Dry Eye
Understanding Antibiotic Resistance
Refractive
Cornea
Glaucoma
OCT
Ocular Allergy
Clinical Diagnosis
Technology

Glaucoma 360: Drug delivery contact lens technology

Name: Glaucoma 360: Drug delivery contact lens technology
Uploaded: 2020-07-17T04:00:00.000Z
Description: ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.

July 17, 2020

Alex Delaney-Gesing

Video

Conferences|GLAUCOMA 360

ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.

ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface diseases, during the 2020 Glaucoma 360 meeting in San Francisco, California.

See more Glaucoma 360 coverage here